Showing results (211-220 of 336) with videos related to
Sort By:
Pageof 34
American Journal of Clinical Pathology|September 25, 2025
Guide to the diagnosis of lymphoid neoplasms in blood and bone marrow: A Bone Marrow Pathology Group approachKathryn Foucar, Adam Bagg, Daniel A Arber, et al.Journal of Digestive Diseases|September 27, 2017
Risk factors of lymph node metastasis in 1620 early gastric carcinoma radical resections in Jiangsu Province in China: A multicenter clinicopathological studyLing Chen, Yao Hui Wang, Yu Qing Cheng, et al.Haematologica|December 1, 2022
DUSP22 rearrangement is associated with a distinctive immunophenotype but not outcome in patients with systemic ALK-negative anaplastic large cell lymphomaLianqun Qiu, Guilin Tang, Shaoying Li, et al.Clinical Lymphoma, Myeloma & Leukemia|August 1, 2024
Expression of CD6 in Aggressive NK/T-cell Neoplasms and Assessment as a Potential Therapeutic Target: A Bone Marrow Pathology Group StudyXiaoxian Zhao, Chad M McCall, Jared G Block, et al.Annals of Hematology|December 30, 2017
Bone marrow findings in blast phase of polycythemia veraJuliana E Hidalgo López, Adrian Carballo-Zarate, Srdan Verstovsek, et al.Journal of Hematology & Oncology|May 9, 2015
TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseasesChi Young Ok, Keyur P Patel, Guillermo Garcia-Manero, et al.Blood Advances|February 6, 2026
Prospective Feasibility Study of Peripheral Blood for MRD Detection in Acute Myeloid Leukemia by Flow CytometryShaoying Li, Nicholas J Short, Wei Wang, et al.Cancers|July 27, 2022
Immunophenotypic and Molecular Features of Acute Myeloid Leukemia with Plasmacytoid Dendritic Cell Differentiation Are Distinct from Blastic Plasmacytoid Dendritic Cell NeoplasmWei Wang, Jie Xu, Joseph D Khoury, et al.Cancers|December 24, 2021
The Leukemic Phase of ALK-Negative Anaplastic Large Cell Lymphoma Is Associated with CD7 Positivity, Complex Karyotype, TP53 Deletion, and a Poor PrognosisLianqun Qiu, L Jeffrey Medeiros, Guilin Tang, et al.Leukemia|May 3, 2023
Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRDPhilip A Thompson, Michael J Keating, Alessandra Ferrajoli, et al.Pageof 34